Impax Laboratories (IPXL) Issues Update on Generic Adrenaclick Auto-Injector Amid EpiPen Headlines

August 30, 2016 8:03 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Impax Laboratories, Inc. (Nasdaq: IPXL) provided an update and additional information to patients, physicians and customers on its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg., the authorized generic of Adrenaclick.

Epinephrine injection, USP auto-injector (also called epinephrine auto-injector) is an emergency injection (shot) of epinephrine used for the treatment of life-threatening allergic reactions known as anaphylaxis.

"With all the recent news related to epinephrine auto-injection products, we are increasing our mission to inform patients, caregivers and the professional community regarding the availability of this epinephrine auto-injector product," said Fred Wilkinson, President and Chief Executive Officer of Impax. "Our epinephrine auto-injector represents a proven, low-cost treatment for patients in the U.S. who require the use of epinephrine products."

The auto-injector is conveniently packaged with numbered and color-coded instructions and is designed for single-dose use by patients and caregivers in an anaphylactic emergency. It is available in a package of two injectors and trainers are available upon request. For more information about the Impax' epinephrine auto-injector and its $0 co-pay program, please visit: or call 855-449-4712.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment